Lineage Cell Therapeutics Stock Price and Value Analysis

Should you buy Lineage Cell Therapeutics stock? (NYSE American:BTX). Let's see how it does in our automated value investing analysis system.

Key Facts

Ticker: BTX (NYSE American)
Current price: $8.52
Sector: Healthcare
Industry: Biotechnology

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Lineage Cell Therapeutics to reach your target.

Target type Target price Target total return %

Current price

Expected annual return (compound annual growth rate, CAGR)

Margin of safety (%)

Target price (Trendshare FV)

Include dividend yield
N/A

BTX Free Cash Flow Trend

Free Cash Flow trendline for BTX — Free Cash Flow trendline for Lineage Cell Therapeutics

Hmm, we can't give any reliable projection for Lineage Cell Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Advantages	Disadvantages	Neutral
This company has amazingly consistent growth! This company is solid.	This stock looks overpriced. This company is not making money.	This company pays no dividend.

Inside the BTX Numbers

	BTX Price (Lineage Cell Therapeutics stock price per share)	$8.52
× PE Ratio Versus Sector The PE ratio measures the reported earnings of a company to its current stock price. While earnings are easy to manipulate on the balance sheet, this ratio gives you a sense of what buyers are willing to pay for the stock—what they believe it will do in the future. Comparing a stock's PE to the average PE of companies in its industry gives you a sense of market sentiment about the stock and how well it fares financially. It's not the only number, nor the most important, but comparing similar companies is valuable. A ratio far above or below that of its peers is significant. Industries are more specific than sectors, so companies within most industries are more similar than are companies within an industry. Be aware that the size and customers of companies are important to their prospects. Close ^[?]	PE Ratio versus Sector	13% higher than other Healthcare stocks
× PE Ratio Versus Industry The PE ratio measures the reported earnings of a company to its current stock price. While earnings are easy to manipulate on the balance sheet, this ratio gives you a sense of what buyers are willing to pay for the stock—what they believe it will do in the future. Comparing a stock's PE to the average PE of companies in its sector gives you a sense of market sentiment about the stock and how well it fares financially. It's not the only number, nor the most important, but comparing similar companies is valuable. A ratio far above or below that of its peers is significant. Be aware that sectors are very broad, with many types of companies in the same sector. Close ^[?]	PE Ratio versus Industry	60% lower than other Biotechnology stocks
× Cash Yield The cash yield of a stock is the ratio of free cash per share—real dollars available after bringing in revenue and paying bills—to the current price of the stock. It's similar to the PE ratio, but it's less prone to manipulation through accounting practices. In general, the less you have to pay to make more money, the better. Close ^[?]	Cash Yield	-2.26%
× Free Cash Flow Jitter The free cash flow jitter of a stock measures how much the company's free cash flow varies from its historical trend, on average. While it's always nice to make more money than you expected, a company with predictable free cash flow is stable and good. A company with wild swings in its free cash flow warrants further research. In general, the lower this number, the better. Close ^[?]	Free Cash Flow Jitter	11%

Recent Insider Activity

Open-market buys and sells reported by Lineage Cell Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date	Insider	Type	Shares	Price
2026-03-12T00:00:00	Culley Brian M (President and CEO)	Buy	15,000	$1.62
2025-01-27T00:00:00	BROADWOOD PARTNERS, L.P.	Buy	7,894,737	$0.76
2025-01-27T00:00:00	BROADWOOD PARTNERS, L.P.	Buy	0	--
2024-11-26T00:00:00	Howe Jill Ann (Chief Financial Officer)	Buy	15,000	$0.59
2024-11-26T00:00:00	Samuel George A. III (General Counsel)	Buy	15,000	$0.60
2024-11-22T00:00:00	Mulroy Michael H.	Buy	40,000	$0.57
2024-11-21T00:00:00	Culley Brian M (President and CEO)	Buy	40,000	$0.60
2024-08-16T00:00:00	Howe Jill Ann (Chief Financial Officer)	Buy	10,500	$0.89
2024-05-24T00:00:00	Culley Brian M (President and CEO)	Buy	10,000	$1.05
2024-02-08T00:00:00	BAILEY DON M	Buy	96,155	$1.04

Estimate Intrinsic Value (DCF)

Project future free cash flow and discount it back to today to compare market price vs intrinsic value. See how compound returns work over time.

📊 Intrinsic Value Calculator (DCF Method)

Calculate the present value of future cash flows to determine stock intrinsic value.

Annual Free Cash Flow ($):

Current or most recent year free cash flow (operating cash - capex)

Expected Annual Growth Rate (%):

Conservative estimate (3-7% for mature companies, 10-20% for growth)

Discount Rate (%):

Required rate of return (8-10% stable, 12-15% growth, 15%+ speculative)

Projection Period (Years):

Longer projections are less certain but may reveal more value

Terminal Value Multiple:

Exit multiple for terminal value (10-15x typical for mature companies)

Calculation Results

Total Intrinsic Value:

Discounted Cash Flows:

Terminal Value (PV):

Year	Future CF	Present Value

How to use this result: Compare the intrinsic value to the current stock price. If intrinsic value is significantly higher than market price (30-50% margin of safety), the stock may be undervalued. Remember, these are estimates based on your assumptions.

Should You Buy BTX?

Learn how to evaluate stocks, understand expected returns, and build a value investing strategy.

See How Returns Compound →

Is Lineage Cell Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Lineage Cell Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Advertisement supports free stock analysis content.

Should You Buy BTX Stock?

Does Lineage Cell Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

We don't yet have enough financial history for Lineage Cell Therapeutics to produce a full worked example. Check back as more data becomes available, or see the current price and research links below.